Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Health Product InfoWatch - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 145974
Later capture
Health Product InfoWatch - Canada.ca
Jan 2, 2026
hc-20260101
ID 428812
updated3 sections changed
3 sections changed0 added0 removed+7 / -14 linesChange ratio: 15%
--- +++ @@ -21,22 +21,16 @@ Reports and Publications MedEffect Canada RSS Feeds and MedEffect e-Notice Latest Issue-March 2025+December 2025 Contents Monthly recap of health product safety information-Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide)-Isotretinoin-Kids by Babyganics SPF 50 mineral sunscreen totally tropical-Lacosamide Injection, USP-Oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban and warfarin)-Unauthorized Health Products+Brukinsa (zanubrutinib), Calquence (acalabrutinib) and Imbruvica (ibrutinib) - Bruton's tyrosine kinase (BTK) inhibitors+Unauthorized health products New health product safety information-Review article-Systemic fluoropyrimidines and severe toxicity in patients with dihydropyrimidine dehydrogenase deficiency-Product monograph update-Arava (leflunomide)+Safety brief+Bruton's tyrosine kinase (BTK) inhibitors and the risk of serious hepatotoxicity Notice of market authorization with conditions-Qalsody (tofersen): Authorization with conditions+Lyvdelzi (seladelpar): Authorization with conditions Scope Reporting Adverse Reactions Helpful links@@ -69,5 +63,4 @@ Telephone: 613-954-6522 Teletypewriter: 1-800-465-7735 (Service Canada) Page details-Date modified:-2025-03-27+2025-12-18